Vorinostat Completed Phase 1 Trials for Acute Promyelocytic Leukemia (APL) / Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00875745Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)